Background
==========

Gastric cancer is the second leading cause of global cancer mortality with nearly one million new cases per year \[[@B1],[@B2]\]. Approximately ten percent of gastric adenocarcinomas are Epstein-Barr virus (EBV) infected, and EBV is considered a class 1 oncogenic pathogen by the World Health Organization \[[@B3]-[@B6]\]. Incidence is rising for those cancers in the proximal segment of the stomach (cardia, corpus) where EBV is more frequently involved \[[@B7]-[@B14]\].

Recent data from the National Cancer Institute's cancer surveillance program shows a worrisome rise in gastric cancer incidence among young adults in the US \[[@B7],[@B8],[@B15]\]. Emerging targeted therapy makes it all the more important to identify infected cancers and to characterize biochemical defects such as ERBB2 overexpression that increases likelihood of response to trastuzumab in metastatic gastric cancer patients \[[@B16]-[@B18]\]. EBV-infected compared to uninfected gastric cancer has a favorable prognosis \[[@B19]\], and clinical trials are beginning to explore virus-targeted therapy such as 1) infused EBV-specific cytotoxic T cells or NK cells \[[@B20]-[@B23]\], 2) reversing the EBV-related methylator phenotype \[[@B24]\], 3) triggering lytic viral replication that could then incite the body's innate and adaptive immune responses to kill infected tumor cells \[[@B25]-[@B33]\], and 4) lytic induction therapy co-administered with antiviral nucleoside analog such as gancyclovir that is phosphorylated and thus activated by viral kinases promoting cytotoxicity \[[@B34]-[@B41]\].

Clinical trials examining the efficacy of targeted therapy would benefit from laboratory assays that help identify candidates likely to respond, and could benefit from laboratory assays that signify the effect of intervention on the intended biochemical pathways. Modern molecular technology now permits clinical-grade analysis of multiple pertinent analytes via RNA expression profiling \[[@B42]\]. Device manufacturers have produced sensitive, specific and customizable probe arrays to simultaneously measure multiple RNAs, including non-coding RNAs like EBV-encoded RNA 1 or 2 that are abundantly expressed in infected tumors. Recent progress in quality assurance strategies have matured to the point that RNA expression profiles are being implemented in clinical laboratory settings \[[@B42]\].

To be practical in clinical settings, an assay must be applicable to routinely collected specimens such as archival, paraffin-embedded tissue \[[@B42]\]. In the current study, we measured viral and human gene expression in archival gastric cancers and in adjacent mucosa and controls to develop a test systems that might be used to reliably characterize signatures predictive of response to targeted therapy. A 96-RNA array test system that we dub the Gastrogenus v1™ panel was customized to measure pertinent latent and lytic viral RNAs alongside clinically relevant human mRNAs that were previously reported to be 1) gastric cancer specific, 2) indicative of inflammation, and/or 3) predictive of response to specific medications. These assays, as well as spiked and endogenous control RNAs, were measured in macrodissected paraffin sections using the Nanostring nCounter test system \[[@B43]-[@B45]\]. Correlative histologic and molecular studies were done to demonstrate that the test system performed as expected. Our findings show that EBV-related cancers express more latent and lytic transcripts than were previously recognized, and that infected cancers have unique biologic characteristics compared with uninfected cancers. Two major subtypes of cancer were found, implying that gastric cancer early detection strategies or monitoring tests could be tailored to detect the pertinent signatures characterizing major molecular subtypes. Finally, pilot data reveals expression of selected viral and cancer-related genes in adjacent non-malignant mucosa, suggesting a field effect that could be important in cancer development or maintenance.

Results
=======

Gene expression profiling was performed on a total of 326 tissues including 187 gastric cancers, 17 lymphoepithelioma-like cervical cancers, and 118 matched non-malignant mucosa from the same surgical procedure (when available). After data normalization, a heat map of the 182 tissues having the best quality RNA, as judged by highest average level of four housekeeping RNAs, revealed patterns of gene expression that differed in gastric *versus* cervical control tissues. Furthermore, in both the gastric and cervical clusters, malignant and non-malignant tissues tended to cluster together, supporting the ability of the nCounter test system to measure clinically important biologic features. (See Figure [1](#F1){ref-type="fig"}.)

![**Expression profiles of 182 tissues for 20 viral genes and 73 human genes.** A heat map displays unsupervised hierarchical clustering of each tissue in a separate column, and each RNA in a separate row. The data is median-centered with red indicating relative overexpression and green indicating relative under-expression for each gene. Correlative data above the map indicates histopathologic classification with further subclassification of the gastric cancer cohort into 14 EBV infected and 104 EBV negative cancers based on EBV DNA levels. Below the map, each gastric cancer is categorized by the proportion of malignant cells, and geographic origin of each tissue is shown.](1750-9378-7-21-1){#F1}

One group of gastric carcinomas overexpressed virtually all of the EBV RNAs. To determine which gastric cancers should be designated as EBV-infected, the 71 tissues with the highest combined levels of *EBER1* and *EBER2* RNA by Nanostring nCounter array were further examined for EBV genome levels within the same tissue by Q-PCR. There was a linear relationship between the amount of *EBER1* and *EBER2* RNA and the amount of EBV genome. (See Figure [2](#F2){ref-type="fig"}.) Our previously established cutoff \[[@B46]\] for the level of EBV genome corresponding to localization of virus to malignant cells resulted in 14 cancers being placed in the EBV-infected category. The remaining gastric cancers were called EBV-negative, and among them the highest recorded RNA levels were 174,016 for *EBER1* and 27,972 for *EBER2*. In contrast, among the EBV-infected gastric cancers the lowest *EBER1* level was 263,589 and the lowest *EBER2* level was 140,081. Proposed cutoffs for identifying a tissue as EBV-infected are shown in Figure [2](#F2){ref-type="fig"}.

![**EBV-encoded RNA levels are high in infected gastric cancer and are proportion to EBV genome level.A**. Box plots of *EBER1* and *EBER2* in benign and malignant tissues reveal that EBV-infected gastric cancer has substantially higher levels of *EBER1* and *EBER2* non-coding RNAs than do uninfected cancers and control tissues. Proposed thresholds for *EBER1* or *EBER2* are shown beyond which a gastric cancer could reliably be designated as EBV-infected. Each dot represents an individual analytic result on a log2 normalized unit (NU) scale. **B**. Pairwise comparison of *EBER1* and *EBER2* RNA levels by Nanostring nCounter array and EBV DNA viral load by Q-PCR reveals a linear association between levels of each of these analytes. Pearson correlation coefficients (P [\>]{.ul}0.86) are shown. The previously validated level of EBV DNA viral load is shown beyond which *EBER* was always localized to malignant cells by *EBER in situ* hybridization (threshold of 10,558 EBV genomes per 100,000 cells, which is equivalent to 13.37 on this log2 scale) \[[@B46]\]. Proposed cutoffs for RNA levels are indicated for both *EBER1* (200,000 NU, or 17.61 on this log 2 scale) and *EBER2* (100,000 NU, or 16.61 on this log2 scale). The one outlier is a non-malignant gastric mucosa that was located adjacent to an EBV-infected gastric cancer, and this mucosa had an EBV DNA load equivalent to that of infected cancers, but it would have been correctly excluded from the EBV-infected cancer group if either *EBER1* or *EBER2* RNA levels were used, or if histology were used, to screen for EBV-related malignancy.](1750-9378-7-21-2){#F2}

Genes overexpressed in EBV-infected versus EBV-negative gastric cancer
----------------------------------------------------------------------

Twenty eight genes were significantly differentially expressed in EBV-infected cancers compared to the EBV negative gastric cancers (p \< 0.05). Interestingly, all 28 were upregulated rather than downregulated in the infected cancers, and this bias is explained at least in part by our selection of positive rather than negative markers of infection when choosing the RNAs to be profiled for this study. Failure to identify any downregulated genes was still surprising given reports that EBV is associated with a CpG island methylator phenotype and additionally the virus can destabilize cellular mRNAs globally \[[@B47]\].

Among the genes significantly upregulated in infected cancers were all 18 of the EBV RNAs tested, as well as cytomegalovirus pp65 (UL83). The cytomegalovirus pp65 (UL83) result is likely to be false positive (suspected to be probe cross hybridization), as evidenced by absence of another lytic RNA, cytomegalovirus pol (UL54), in the EBV-infected cancers. Furthermore, UL83 but not UL54 was expressed in EBV infected but not in EBV-negative cell line controls (data not shown). Another possible explanation for false positive viral RNA expression is probe crossreactivity with viral DNA. Nine human RNAs were significantly upregulated in EBV-infected compared to EBV negative gastric cancers: *FCER2, MS4A1 (CD20), PLUNC, TNFSF9, TRAF1, CXCL11, IFITM1, PPARG*, and *FCRL3*. (See Figure [3](#F3){ref-type="fig"}).

![**Multiple human RNAs are over-expressed in EBV-infected gastric cancer compared to EBV-negative cancer.** Box plots demonstrate the human RNAs levels in infected compared to uninfected gastric cancers and controls that include lymphoepithelioma-like cervical cancer, cervical mucosa, and benign gastrointestinal mucosa. Each dot represents an individual analytic result on a log2 normalized unit scale.](1750-9378-7-21-3){#F3}

Genes differentially expressed in gastric cancer compared to non-malignant gastrointestinal mucosa
--------------------------------------------------------------------------------------------------

Twenty six genes were significantly dysregulated in gastric cancer compared to non-malignant gastric mucosa (p \< 0.05). The human RNAs upregulated in gastric cancer were *INHBA, SPP1, THY1, SERPINH1, CXCL1, FSCN1, COL1A1, SPARC, COL1A2, PTGS2 (COX2), BBC3, ICAM1, TNFSF9, MYC, SULF1, SLC2A1, COL3A1, PCNA, and TYMS*, while the downregulated RNAs were *CDH1 (E-cadherin), CLDN18*, *CHGA* (chromogranin), *PTEN, SDC1* (CD138) and *GAST* (gastrin). The only viral factor that was differentially expressed was *BLLF1* which was significantly higher in cancer than in non-malignant gastric mucosa (p = 0.004). *BLLF1* encodes the late viral envelope protein gp350/220, suggesting that virions are significantly more prevalent in cancer than in non-malignant gastric tissue. *BLLF1* was not specific for gastric cancer, however, as it was also expressed in some benign and malignant cervical tissues, as well.

Genes associated with gastric cancer compared to lymphoepithelioma-like cervical cancer
---------------------------------------------------------------------------------------

Nine genes were significantly dysregulated in gastric cancer compared to lymphoepithelioma-like cervical cancer (p \< 0.05). The seven RNAs upregulated in gastric cancer were *CLDN18, EPCAM, REG4, BBC3, OLFM4, PPARG*, and *CDH17*, while the two downregulated genes were *IFITM1* and *HIF1A*.

Patterns of latent and lytic viral gene expression in EBV infected gastric cancers
----------------------------------------------------------------------------------

The 14 EBV-infected gastric cancers in this study consistently coexpressed virtually all of the EBV latent and lytic genes, which is somewhat surprising given that prior literature describes a somewhat restricted latency pattern \[[@B48]-[@B51]\]. It is feasible that the Nanostring nCounter analytic technology is more sensitive than traditional methods of detection.

The most highly expressed viral RNA was *EBER1* at an average of over 1 million normalized units per EBV-infected cancer tissue, followed by *EBER2*, *BRLF1* and *EBNA1* from of the Q promoter. *EBNA2* was the least expressed viral RNA with a mean expression of only 10 normalized units per infected tissue and *EBNA2* was completely absent in 8 of the 14 infected gastric cancers. Patterns of viral gene expression are depicted in Figure [4](#F4){ref-type="fig"}.

![**Latent and lytic EBV genes are co-expressed in gastric cancer.** A portion of the heat map from Figure [1](#F1){ref-type="fig"} is displayed in high contrast to decipher relative expression levels of EBV genes in the 14 EBV-infected gastric cancers and surrounding specimens. All tissues are gastric cancers except a single non-malignant gastric mucosa, shown in grey, dissected from the same paraffin block as an EBV-infected gastric cancer. Mean expression level of each RNA in the EBV-infected gastric cancer cohort is shown to the right of each gene symbol.](1750-9378-7-21-4){#F4}

Geographic origin and tumor cell proportion are not preferentially associated with EBV status of gastric cancer
---------------------------------------------------------------------------------------------------------------

Below the heat map in Figure [1](#F1){ref-type="fig"} is the distribution of gastric cancer cases by geographic origin from Honduras (n = 86), Japan (n = 5), or the United States (n = 17). There was no significant association between geographic origin and EBV-positive *versus* negative clustering of gastric cancers (Fisher's exact test p = 0.9), suggesting that geographic origin is not the major driver of hierarchical clustering.

The bottom of Figure [1](#F1){ref-type="fig"} also shows the distribution of EBV-infected *versus* EBV-negative gastric cancers classified by the proportion of malignant cells input into the expression profiling assay. There was no significant association between the proportion of malignant cells and the EBV-infected *versus* EBV-negative groups of gastric cancer. Surprisingly, the cancer tissues with low malignant cell content did not preferentially cluster with the non-malignant gastric tissues. Cancers with low malignant cell content (1 to 25% malignant cells) were distributed across various segments of the heat map along with cancers with medium (26 to 50%) or high (\>50%) malignant cell content (Fisher's exact test p = 0.5), suggesting that overall transcriptome features outweigh tumor cell proportion as the driver of hierarchical clustering.

Keeping in mind that the lymphoepithelioma-like cervical cancers in this study were rich in lymphoid stroma, as are many EBV-infected gastric cancers, it is remarkable that these two classes of cancer clustered separately from each other and also achieved reasonably good separation from adjacent non-malignant mucosa. For most genes in the panel, there is considerable overlap in levels across disease types. While profiles are more informative and more convincing than are individual transcript results, there is some overlap in profiles as well, signifying that profiling assay results must be correlated with histologic features in order to accurately classify a tissue as benign or malignant.

Pharmacogenetic predictors and druggable targets
------------------------------------------------

EBV infection itself is considered an actionable target, at least for the 14/108 (13%) infected gastric cancers we identified. This study demonstrates a novel way to identify virus-infected cancers by RNA profiling of paraffin sections so that prognostic and predictive information may be considered in patient management decisions. Cellular factors of pharmacogenetic potential include the HIF pathway, *SPARC, TYMS, FCGR2B, MET,* and *ERBB2 (Her2)*. (See Figure [5](#F5){ref-type="fig"}). Compared with gastric cancers, cervical cancers tend to have higher levels of *HIF1A* indicating hypoxia response, although equally high levels in non-malignant cervical mucosa raise the possibility of *ex vivo* stimulation of this oxygen-sensing factor. Further study is needed to distinguish technical factors from *in vivo* upregulation that would warrant consideration of angiogenesis inhibitors.

![**Some gastric cancers have significant dysregulation of factors that show promise as pharmacogenetic predictors.** Box plots demonstrate expression of selected pharmacogenetic targets in infected versus non-infected gastric cancers as well as non-malignant gastric mucosa and cervical histopathologies. Each dot represents an individual analytic result on a log2 normalized unit scale.](1750-9378-7-21-5){#F5}

We confirmed that *SPARC* is upregulated in gastric cancer compared to benign gastric mucosa. Response to docetaxel, a taxane drug that inhibits mitotic spindle assembly, is reportedly impacted by the amount of SPARC protein expression in gastric cancer \[[@B52]\]. Gastric and cervical cancers both had higher *thymydylate synthase (TYMS)* than did their respective benign mucosal counterparts. High *TYMS* levels reportedly contributes to acquired resistance to 5FU combination therapy \[[@B53]\].

A few gastric cancers had extremely high levels of the Fc receptor, *FCGR2B*, which could affect drug internalization and pharmacodynamics of therapeutic antibodies such as cetuximab *in vivo.* Four gastric cancers strongly expressed *MET,* and an additional eight cases strongly overexpressed expressed *ERBB2 (Her2)*, raising the possibility that this assay could predict response to tyrosine kinase inhibitor therapy.

Discussion
==========

This study used modern molecular methods to examine a large panel human and viral RNAs in gastric cancer. To our knowledge, this is the largest panel of viral gene products to be examined in concert with human RNAs in archival, paraffin embedded tissues. The EBV-infected subtype of gastric cancer is dramatically evident in the corresponding heat map created by unsupervised clustering, and EBV infection was confirmed by high EBV DNA viral loads in these tissues. Expression of selected viral and human genes in the cancers confirmed several known virus- and cancer-related effects and also revealed novel findings that shed light on pathogenesis and possible disease management strategies.

Surprisingly, the infected gastric cancers overexpressed all 18 of the latent and lytic EBV genes that were tested. We discovered high levels of *BRLF1* RNA (encoding the immediate early viral protein triggering lytic replication in concert with BZLF1) and moderately high levels of *BXLF1* (the viral thymidine kinase that converts penicyclovir to a toxic form, suggesting a mechanism for therapy) \[[@B54]\]. *BLLF1* (encoding the late viral envelope protein gp350/220) was expressed at moderate levels that were nevertheless significantly higher than in non-malignant mucosa, suggesting that EBV lytic infection is not abortive but rather is capable of producing the late viral envelope protein gp350/220. Among the latent genes, *EBNA1* from the Q promoter, *EBNA-LP, and EBNA3C* transcripts were most prevalent. *EBNA2* was focally detected at low level but was still significantly higher in infected than in uninfected gastric cancers. Prior histochemical work has generally not revealed protein-level expression of the EBNAs or lytic viral gene products, so further work is required to learn if these virally encoding RNAs are localized to malignant cells, lymphocytes, or possibly even to exosomes or virions in the extracellular milieu.

Compared to uninfected cancers, the infected cancers had significant upregulation of nine cellular factors (*FCER2, MS4A1 (CD20), PLUNC, TNFSF9, TRAF1, CXCL11, IFITM1, PPARG*, and *FCRL3*), implying that EBV is not an innocent bystander with respect to biochemical impact. The virus-associated changes we found were in pathways known to viral oncologists, namely NFKB and NOTCH signaling (*FCER2, TRAF1, PPARG*) and mucosal immune response (*PLUNC, TNFSF9, CXCL11, IFITM1, FCRL3*). MS4A1 (CD20) is B cell specific, reminding us that some of the factors upregulated in EBV-infected compared to uninfected gastric cancers could derive from stromal elements rather than from malignant epithelial cells. *PLUNC* was previously described as a tumor marker for gastric and nasopharyngeal carcinomas, and it encodes a secreted protein involved in innate immune response \[[@B55]-[@B57]\]. TNFSF9, a cytokine of the tumor necrosis factor family, stimulates T cell activation and triggers IFNG production which in turn induces the proinflammatory chemokine CXCL11 and the innate antiviral factor IFITM1. PPARG is as a nuclear receptor controlling glucose metabolism and microtubule networks, and it is a promising target for inhibitory drugs \[[@B58]\]. The *FCRL3* immune response gene is mutated in autoimmune diseases such as rheumatoid arthritis, lupus, and Grave's disease.

Our findings support the work of Lee *et al* who found distinct human expression patterns in infected *versus* uninfected gastric cancers \[[@B10]\]. Although their study targeted protein and ours targeted RNA, our findings agreed with theirs for 4 of the 5 factors in common between the two studies (*BCL2, PTEN, CDH1, PTGS2*). There was a potential discrepancy for *ERBB2* that was significantly less frequently expressed in infected compared to uninfected gastric cancers when tested at the protein level \[[@B10]\], whereas the current study showed no significant difference at the RNA transcript level. Confounding factors include 1) the proportion of tumor cells present in the specimens evaluated, 2) different criteria for categorizing expression status, and 3) RNA versus protein targets.

In general, the array technology that was used in this study worked remarkably well in generating RNA profiles that were believable by virtue of distinguishing known benign *versus* malignant and gastric *versus* cervical histopathologies. Furthermore, co-expression of analytes in the same pathway or by the same infectious agent makes sense from a pathobiology and virology perspective. Interestingly, all of the cervical tissues clustered together, and benign and malignant cervical lesions were largely segregated even though the Gastrogenus v1™ test panel had not been specifically designed to achieve these endpoints. Lack of multiple co-expressed EBV mRNAs in cervical tissues reinforced what we knew about their EBV-negativity by the gold standard *EBER in situ* hybridization assay.

Among the seven genes that were significantly more expressed in gastric cancer (regardless of infection status) compared to lymphoepithelioma-like cervical cancer, four were previously reported as gastric cancer markers (*CLDN18, REG4, OLFM4, CDH17*) \[[@B55],[@B59]-[@B63]\]. Two others (EPCAM epithelial cell specific trans-membrane glycoprotein, and PPARG chemokine), as well as REG4, are being explored for targeted cancer therapy \[[@B64]-[@B66]\]. The last of the seven, BBC3 (also called p53 up-regulated modulator of apoptosis, or PUMA) is reportedly upregulated by EBV LMP2A and reigned in by EBV miR-BART5 in cell line models \[[@B67],[@B68]\], suggesting that this BCL2 family member is tightly regulated by the virus.

One of the two RNAs that was significantly higher in cervical compared to gastric cancer was *IFITM1*, which you may recall was also found to be overexpressed in infected compared to uninfected gastric cancers. Further work is needed to explore if cervical cancers (presumably human papillomavirus-infected) and EBV-infected gastric cancers share a common virus-related mechanism for overexpression of this innate immune response factor. The other gene significantly overexpressed in cervical compared with gastric cancer was *HIF1A* whose expression was associated with that of four downstream angiogenesis mediators in our panel (*VEGFA, SLC2A1, SLC2A3* and *EPAS1*) as evidenced by positive Pearson's correlation coefficients (data not shown). If confirmed to be operative *in vivo*, HIF pathway stimulation implies that angiogenesis inhibitors are worth investigating.

Benign *versus* malignant gastric tissues tend to cluster separately on the heat map, with some exceptions. Field effect \[[@B69]\] or exosomal transfer of factors to adjacent regions of the local environment \[[@B70],[@B71]\] could explain why some cancers and adjacent reactive tissues had similar profiles. While macrodissection was used to carefully separate benign from malignant lesions, we cannot exclude occult malignancy as a contributor to aberrant clustering.

Among the 19 genes significantly upregulated in gastric cancer compared to adjacent non-malignant gastric mucosa, most were previously reported as gastric cancer specific markers \[[@B72]-[@B76]\], and we now confirm that their upregulation is detectable in archival paraffin-embedded tissue. Lower levels of *GAST* (gastrin) RNA in cancer tissues could help explain the concomitant loss of the gastrin signaling factor *CHGA* (chromogranin). The most consistently downregulated factor in gastric cancer *versus* adjacent benign mucosa was the tumor suppressor gene *CDH1 (E-cadherin)* suggesting either 1) *CDH1* promoter hypermethylation \[[@B77]\], 2) rare germline mutation of *CDH1* associated with heritable predisposition to gastric cancer \[[@B78]\], or 3) downregulation of *CDH1* by EBV LMP1 as described in cell line models \[[@B79]\].

LMP1 was previously reported to be absent in infected gastric cancer except in rare cases \[[@B50],[@B51],[@B80],[@B81]\]. It was therefore surprising that Nanostring nCounter array profiling showed consistent albeit low level expression of *LMP1* RNA along with virtually all of the other EBV RNAs that were tested in the infected gastric cancers. Coordinated co-expression of multiple viral genes argues that the expression is true positive. Our microarray results raise the possibility that the viral RNAs we detected are not encoding proteins or that the proteins are 1) only transiently expressed, 2) rapidly degraded, 3) localized to rare cells that are promptly recognized and destroyed by the immune system, or 4) present at such low level that traditional assays are too insensitive to detect them \[[@B82]\]. The nCounter test system manufacturer claims analytic sensitivity equivalent to that of rtPCR \[[@B43]\].

While most viral genes were expressed almost exclusively in the infected gastric cancer cohort, *EBER1* and *EBER2* were commonly expressed in each one of the benign and malignant gastric and cervical cohorts, albeit at much lower levels than was seen in each of the EBV-infected gastric cancers. Indeed, our study revealed a novel way to identify EBV-infected gastric cancer by measuring *EBER1* and/or *EBER2* RNA in archival tissue, and we have proposed thresholds that successfully distinguish infected from uninfected gastric cancer.

Support for active viral infection in infected gastric cancer patients comes from serologic evidence of higher titers against viral capsid antigen compared to EBV-negative gastric cancer patients and benign controls \[[@B83]\]. Low level lytic infection was previously described in mucosal lymphoid cells \[[@B31],[@B82],[@B84]\] and in infected gastric epithelial cell lines \[[@B85]\]. BARF1 is known to be expressed in gastric cancer where it is proposed to act as a latent rather than a lytic factor \[[@B50],[@B51]\]. Using sensitive rtPCR technology, multiple EBV lytic transcripts were detected by Luo et al in gastric cancer tissues \[[@B50]\]. Whether active replicative infection occurs in malignant epithelial cells or in lymphoid cells remains uncertain since histochemical stains have failed to reveal a cellular source of lytic factors in gastric tissues \[[@B82]\].

While EBV-infected gastric cancer is biologically distinct from EBV-negative cancer in some respects, the infected counterparts still share many of the classic features previously identified as being characteristic of gastric cancer, such as specific collagens (*COL1A1, COL1A2, COL3A1), SULF1, THY1, SPP1, INHBA*, and *SPARC*\[[@B76]\]. These pan-gastric cancer markers might be exploited for early diagnosis or for monitoring tumor burden during therapy, especially when multiple such markers are tested in concert to maximize specificity while still capturing the heterogeneity of the disease. Biomarkers for the EBV-infected subset, such as EBV DNA and the highly expressed viral *EBER1EBER2EBNA1*, and *BRLF1* RNAs, as well as associated cellular factors confirmed in this study, represent promising targets for early detection. To the extent that any of these factors circulate in blood, they might serve as non-invasive indicators of disease analogous to what has already been achieved for two other EBV-infected neoplasms\-- post transplant lymphoproliferative disorder and nasopharyngeal carcinoma. In both of these disorders, Q-PCR of circulating EBV DNA facilitates early diagnosis and in monitoring efficacy of therapy \[[@B86]-[@B88]\]. High levels of *EBER1* and *EBER2* RNA were measurable in plasma of 89% of nasopharyngeal carcinoma patients \[[@B89]\].

Antiviral therapy is becoming more accepted given its biologic underpinnings\-- the viral genome is present in *every* malignant cell of a given infected cancer\-- thus making the virus one of the most appealing therapeutic targets in our armamentarium. Off-the-shelf cytotoxic T cells are now available to treat selected EBV-related malignancies \[[@B90],[@B91]\]. Early clinical trial data demonstrate the merits of lytic induction therapy \[[@B33],[@B92],[@B93]\]. Assessment of lytic induction by panels of tests such as the microarray system described herein could be useful for measuring the biochemical impact of an intervention and its efficacy.

Applicability of the Nanostring nCounter system to archival paraffin embedded tissue was previously reported by others \[[@B43],[@B44]\], but ours is the first study to examine viral and human RNAs in concert. The test system's ability to rapidly profile multiple RNAs generates rich data relevant to viral oncology and patient care. A major advantage is suitability for routine fixed tissue specimens including small biopsies that were previously collected, processed and stored using customary clinical methods. While microscopy is essential to assuring that representative tissue is input into the assay, the noteworthy flexibility of the test system with regard to malignant cell proportion promotes it use in clinical settings. Panels of analytes could be tailored to support different intended uses such as suitability of a subject for a specific clinical trial, or monitoring efficacy of a given regimen in serial specimens.

Conclusions
===========

This study demonstrates the promise of array technology to understand associations between viral and cellular factors in naturally infected gastric cancers. We showed major biologic differences between infected and uninfected cancers, between benign and malignant tissues, and between gastric and cervical cancers. While prior work indicates that the virus lies latent in malignant tissue, we found evidence of active lytic infection and virus-associated cellular changes that should be further explored. Large panels of complementary tests promote confidence in the findings and pave the way for design of practical panels to be applied in clinical trials and, once validated as useful, implemented in routine patient care.

Materials and methods
=====================

Patient tissue and macrodissection
----------------------------------

Formalin-fixed, paraffin-embedded gastric adenocarcinoma tissues from the clinical archives of three hospitals in disparate parts of the world were assembled, including 30 from the University of North Carolina Hospitals in Chapel Hill, USA, 133 from Western Regional Hospital in Santa de Rosa, Honduras, and 24 from Wakayama Medical University, Wakayama, Japan. As a control, 16 paraffin embedded tissues diagnosed as lymphoepithelioma-like carcinoma of the uterine cervix were retrieved from the archives of the University of North Carolina Hospitals in Chapel Hill. All studies were done with approval of our Institutional Review Board, University of North Carolina Biomedical IRB.

On each paraffin block, nine formalin-fixed, paraffin-embedded tissue sections, each 5uM thick, were cut. One section was stained with hematoxylin and eosin so that a pathologist could mark areas containing at least 50% malignant cells among all cells present. Cancers with less tumor were still included in the study after further categorizing them as having either 1 to 25% or 25 to 50% malignant cells in marked areas of the slide. A scalpel was used to scrape and combine the marked malignant cell-rich areas from 8 unstained sections. When non-malignant mucosa from the same surgical procedure was available, the non-malignant tissue was macrodissected from unstained sections and separately prepared for expression profiling.

Nucleic acid isolation and expression profiling
-----------------------------------------------

Total nucleic acid was extracted using the HighPure miR Isolation kit using the manufacturer\'s instructions (Roche Applied Science). Nucleic acid quality and purity were assessed by Nanodrop spectrophotometry, and a 500 ng aliquot was spiked with each of three exogenous control RNAs designed by the External RNA Controls Consortium (ERCC number 113, 147 and 163) and then frozen until RNA expression analysis on the nCounter system according to manufacturer instructions (Nanostring). Recovery of the spiked ERCC RNAs served as a control for integrity of the stored nucleic acid. Furthermore, recovery of 6 different synthetic RNAs built into the Nanostring reagent system provided confidence that that Nanostring nCounter analytic test system performed as expected.

The instrument generated a direct digital readout of the number of each RNA molecule based on hybridization of patient nucleic acid with multiplexed pairs of capture and reporter probes tailored to each RNA of interest, followed by washing away excess probes, immobilization of biotinylated capture probe-bound RNAs on a surface, and scanning color-coded bar tags on each reporter probe. A custom panel of 96 RNA assays designed for this study included 73 human mRNAs, 7 latent and 9 lytic EBV mRNA transcripts as well as *EBER1* and *EBER2* non-coding RNAs, two cytomegalovirus mRNAs, and 3 spiked ERCC RNA controls. The target human mRNAs were chosen after literature review to represent the following characteristics, 1) gastric cancer-specific analytes, 2) EBV-dysregulated factors, 3) potential pharmacogenetic biomarkers, 4) inflammatory cell markers, and 4) housekeeping controls. (See Table  [1](#T1){ref-type="table"}).

###### 

RNAs targeted in the GastroGenus v1™ panel

  **Gene symbol**                                                          **Alternate symbol**   **Function or utility**                                    **Reference sequence or GeneID**
  ------------------------------------------------------------------------ ---------------------- ---------------------------------------------------------- ----------------------------------
  **Gastric cancer specific RNAs and gastrin signalling factors**                                                                                            
  REG4                                                                                            Cell regeneration and growth                               NM_032044.3
  OLFM4                                                                                           Tumor growth & cell adhesion, olfactomedin                 NM_006418.3
  DKK4                                                                                            Embryonic development                                      NM_014420.2
  ODAM                                                                     APin                   Enamel mineralization                                      NM_017855
  CSAG2                                                                                           Drug resistance                                            NM_001080848.2
  MIA                                                                                             Growth inhibition                                          NM_006533.2
  CYP2W1                                                                                          Drug metabolism, cytochrome p450                           NM_017781.2
  HORMAD1                                                                                         Cell cycle regulation                                      NM_032132.3
  MMP10                                                                                           Matrix metallopeptidase, remodeling                        NM_002425.2
  FUS                                                                                             mRNA/miRNA processing                                      NM_004960
  CLDN18                                                                                          Tight junction component, claudin                          NM_001002026
  SERPINH1                                                                                        Collagen synthesis, peptidase inhibitor, heat shock        NM_004353
  THY1                                                                                            Control of inflammatory cell recruitment                   NM_006288
  INHBA                                                                                           Inhibin, inhibits hormone secretion and cell growth        NM_002192
  CXCL1                                                                                           Immune development and homeostasis, chemokine              NM_001511
  SPARC                                                                    osteonectin            Protects from apoptosis, docetaxel response                NM_003118
  SPP1                                                                                            Osteogenesis, secreted phosphoprotein                      NM_000582
  SULF1                                                                                           Cell signaling, sulfatase                                  NM_015170
  COL1A1                                                                                          Type I collagen component                                  NM_000088
  COL1A2                                                                                          Type I collagen component                                  NM_000089
  COL3A1                                                                                          Type III collagen component                                NM_000090
  CDH1                                                                     E-Cadherin             Cell adhesion, mutated in heritable gastric cancer         NM_004360
  EPCAM                                                                                           Epithelial cell adhesion                                   NM_002354
  GAST                                                                                            Stimulates stomach acid secretion                          NM_000805
  CDH17                                                                                           Peptide transporter, gastrin signalling                    NM_004063.3
  CHGA                                                                                            Neuroendocrine cell, gastrin signalling                    NM_001275
  PTGS2                                                                    COX2                   Prostaglandin synthesis, gastrin signaling, druggable      NM_000963.1
  MYC                                                                                             Cell cycle regulator, gastrin signalling                   NM_002467.3
  CCND1                                                                    BCL1                   cell cycle regulator, gastrin signalling                   NM_053056.2
  **EBV-related inflammatory response genes and NFKB signaling factors**                                                                                     
  PLUNC                                                                                           Gastric and nasopharyngeal carcinoma                       NM_130852.2
  MET                                                                                             Receptor tyrosine kinase, ongogene, drug target            NM_000245.2
  BACH1                                                                                           Transcription factor                                       NM_206866
  BBC3                                                                     PUMA                   p53 target, pro-apoptotic target of EBV mir-BART5          NM_014417
  CXCL11                                                                                          Leukocyte trafficking, target of EBV mir-BHRF1-3           NM_005409
  CDKN1A                                                                   P21, WAF1              Cyclin-dependent kinase inhibitor, EBV miR target          NM_000389.2
  FCRL3                                                                                           Immune regulation, Fc receptor-like tyrosine kinase        NM_052939
  CD70                                                                                            T and NK cell activation, TNF ligand                       NM_001252
  FSCN1                                                                                           Cell morphology and motility                               NM_003088
  TNFSF9                                                                                          Antigen (Ag) processing, TNF ligand cytokine               NM_003811
  BCL2L11                                                                  BIM                    Activator of apoptosis, BCL2-like                          NM_006538
  PTEN                                                                                            Tumor suppressor, EBV miR target                           NM_000314.3
  PCNA                                                                                            DNA replication and repair, cell proliferation indicator   NM_182649.1
  GPR183                                                                                          G protein-coupled receptor, EBV-induced                    NM_004951
  MX1                                                                                             Mediates antiviral response, interferon response           NM_001144925
  IFITM1                                                                                          Innate antiviral and interferon response                   NM_003641
  FCGR2B                                                                                          Phagocytosis & antibody production                         NM_004001
  ICAM1                                                                                           NFKB regulated, cell adhesion                              NM_000201.2
  TRAF1                                                                                           NFKB regulated, TNF receptor                               NM_005658.3
  FCER2                                                                    CD23                   NFKB-regulated B cell differentiation, IgE receptor        NM_002002.4
  IL10                                                                                            Anti-inflammatory cytokine regulates NFKB signalling       NM_000572.2
  **Hematopoietic cell markers**                                                                                                                             
  PTPRC                                                                    CD45                   Pan-hematopoietic cell marker, T & B cell signaling        NM_002838
  MS4A1                                                                    CD20                   B cell marker, differentiation                             NM_021950
  IGLL1                                                                    CD179B                 B cell marker, growth                                      NM_020070
  BANK1                                                                                           B-cell marker, receptor-induced calcium mobilization       NM_017935
  FAM129C                                                                                         B cell marker                                              NM_173544
  MUM1                                                                     IRF4                   Late stage B cell, signaling & differentiation             NM_032853
  SDC1                                                                     CD138                  Plasma cell, also epithelial cell binding and signaling    NM_001006946
  CD4                                                                                             Helper T cells, MHC class II antigen processing            NM_000616.3
  CD8A                                                                                            Suppressor T cells, MHC class I antigen processing         NM_001768
  CD3G                                                                     \--                    Pan T cell marker, intracellular signaling                 NM_000073
  GPR56                                                                                           NK cell marker in peripheral tissues                       NG_011643.1
  **Pharmacogenetic factors impacting drug response**                                                                                                        
  ERBB2                                                                    HER2                   Kinase-mediated signaling, trastuzumab target              NM_004448.2
  PPARG                                                                                           Glucose and lipid metabolism                               NM_138711.3
  TYMS                                                                                            Thymidylate synthase, DNA repair, 5FU response             NM_001071.2
  HIF1A                                                                                           Systemic response to hypoxia                               NM_001530.2
  EPAS1                                                                                           Angiogenesis                                               NM_001430
  VEGFA                                                                                           Mitogen for endothelial cells                              NM_001025366
  SLC2A3                                                                   GLUT3                  Glucose transporter                                        NM_006931.2
  SLC2A1                                                                   GLUT1                  Glucose transporter                                        NM_006516.2
  **Epstein-Barr virus (EBV) RNAs:**                                       NC_007605.1                                                                       
  LMP1                                                                     BNLF1                  TNF/CD40 signalling, latent phase                          3783750
  LMP2A                                                                                           Cell survival , latent phase                               3783751
  EBNA1                                                                    BKRF1                  Viral persistence, episome, latent phase                   3783709
  EBNA1,QUK                                                                                       Q promoter variant, viral persistence, latent phase        3783774
  EBNA2                                                                    BYRF1                  Transactivator, latent phase                               3783761
  EBNA3A                                                                   BERF1                  Immortalization, latent phase                              3783762
  EBNA-LP                                                                                         Transactivator, latent phase                               3783746
  EBER1                                                                                           Non-coding RNA inhibits apoptosis, latent phase            AJ507799.2 - 6629.6795
  EBER2                                                                                           Non-coding RNA inhibits apoptosis, latent phase            AJ507799.2 - 6956.7128
  BZLF1                                                                    Zta, Zebra             Immediate early transactivator of lytic replication        3783744
  BMRF1                                                                                           Early lytic DNA polymerase processivity factor, TF         3783718
  BHRF1                                                                                           Viral BCL2 inhibits apoptosis, early lytic phase           3783706
  BCRF1                                                                                           Viral interleukin 10 homologue                             3783689
  BARF1                                                                                           Soluble CSF1 receptor homologue, early lytic phase         3783772
  BRLF1                                                                    Rta                    Immediate early transactivator of lytic replication        3783727
  BLLF1                                                                    gp350/220              Viral entry via CD21 receptor, late lytic phase            3783713
  BALF5                                                                                           Viral DNA polymerase, early lytic phase                    3783681
  BXLF1                                                                                           Thymidine kinase, early lytic phase                        3783741
  **Human cytomegalovirus (CMV) RNAs:**                                    NC_006273.2                                                                       
  UL83                                                                     pp65                   Late lytic phase                                           3077579
  UL54                                                                     pol                    CMV DNA polymerase, early lytic phase                      3077501
  **Housekeeper RNAs**                                                                                                                                       
  CLTC                                                                                            Intracellular trafficking & endocytosis                    NM_004859.2
  GUSB                                                                                            Glucuronidase degrades glycosaminoglycans                  NM_000181.1
  TBP                                                                                             Transcription initiation by TATA box binding protein       NM_003194.3
  HPRT1                                                                                           Generation of purine nucleotides                           NM_000194.1

Following analysis, raw expression data was first adjusted by subtracting the mean counts of 6 negative controls in the Nanostring reagent system. (Two additional negative controls were omitted because of cross-reactivity with *EBERs*.) Negative values were adjusted to zero, and then data was normalized for 1) technical variation using the average of 6 positive controls in the Nanostring reagent system as recommended by the manufacturer, and 2) endogenous RNA amount or quality using the average of four housekeeping RNAs (*HPRT1, GUSB, CLTC* and *TBP*). To promote accurate profiling, only those 182 specimens with the highest average housekeeping RNA content were used for statistical analysis, while another 140 specimens were excluded based on low average housekeeping RNA levels. The cohort of cases for statistical analysis was comprised of 124 cancers and 58 non-malignant mucosae, while cohort of cases excluded from statistical analysis because of poor RNA quality was comprised of 80 cancers and 60 non-malignant mucosae. Heat maps were created to show median-centered expression of each gene using Cluster 3.0 and JavaTreeView software algorithms applied to log2 transformed data.

EBV Q-PCR and *EBER* in situ hybridization
------------------------------------------

To measure viral DNA load, an aliquot of the same total nucleic acid extract that had been used for RNA profiling was subjected to quantitative PCR targeting the BamH1W segment of the EBV genome \[[@B94]\]. A parallel Q-PCR assay targeting the human *APOB* gene controlled for efficacy of DNA extraction was used to normalize for the number of cells represented in the PCR assay as previously described \[[@B94]\]. Amplification products were measured on an ABI Prism 7500 Real-Time PCR instrument using TaqMan probe and Sequence Detection System software (Applied Biosystems) \[[@B82]\], and results reported in copies of EBV DNA per 100,000 cells.

Viral localization to malignant cells was tested using EBV-encoded RNA *(EBER) in situ* hybridization on paraffin sections (BOND assay, Leica Microsystems) \[[@B95]\]. As a quality control, RNA preservation was confirmed in parallel *in situ* hybridization to poly A tails by oligo-dT probe.

Statistics
----------

Unsupervised hierarchical clustering of gastric cancer tissues revealed the EBV-infected and uninfected molecular classes of gastric cancer. Three additional tissue classes (cervical cancer, and benign gastrointestinal or cervical mucosae) were defined by clinicopathologic criteria. In box plots, the median and middle two quartiles are surrounded by whiskers depicting outliers which are far above or below the interquartile range (IQR) by \> Q3 + 1.5\*IQR or \< Q1-1.5\*IQR, respectively. Genes significantly differentially expressed among groups were identified using non parametric Mann-Whitney tests and the p-values were adjusted using the Bonferroni correction to account for multiple comparisons. A given RNA was classified as significantly differentially expressed if its Bonferroni adjusted p value was \<0.05 and it was more differentially expressed than any single one of the four housekeeping RNAs.
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